Inhibition of gastric tumor growth by a novel Hsp90 inhibitor

Chunwan Lu, Di Liu, Jing Jin, Hemantkumar Deokar, Yi Zhang, John K. Buolamwini, Xiaoming Yu, Chunhong Yan, Xiaoguang Chen

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

Heat shock protein 90 (Hsp90) is a molecular chaperone engaging in multiple cellular signaling by stabilizing oncoproteins (e.g. Akt and c-Raf) in tumor cells. Whereas Hsp90 inhibitors such as 17-AAG exert promising antitumor effects in clinical trials, current efforts focus on developing agents targeting Hsp90 with improved efficacy and lower toxicity. Using a fluorescence polarization assay, we screened over a hundred of synthetic small molecules and identified a resorcinol derivative LD053 that bound the Hsp90 ATP-binding pocket. The binding of LD053 to Hsp90 dissociated the co-chaperone protein cdc37 from Hsp90, resulting in destabilization of Akt and c-Raf and subsequent inhibition of PI3K/Akt and c-Raf/Mek/Erk signaling in BGC823 gastric cancer cells. As a consequence, LD053 decreased cancer cell viability and induced apoptosis evidenced by increased subG0/G1 cell population and increased cleavage of caspase 3 and PARP. Interestingly, normal human cells appeared insensitive to LD053 treatments. Consistent with its in vitro anticancer activities, LD053 significantly inhibited growth of BGC823 xenografts in nude mice without apparent body weight loss. These results thus demonstrate that LD053 is a novel Hsp90 inhibitor and has potential to be used to treat gastric cancer.

Original languageEnglish (US)
Pages (from-to)1246-1256
Number of pages11
JournalBiochemical Pharmacology
Volume85
Issue number9
DOIs
StatePublished - May 1 2013
Externally publishedYes

Fingerprint

HSP90 Heat-Shock Proteins
Tumors
Stomach
Cells
Growth
Neoplasms
tanespimycin
Stomach Neoplasms
Cell signaling
Molecular Chaperones
Fluorescence Polarization
Oncogene Proteins
Phosphatidylinositol 3-Kinases
Heterografts
Nude Mice
Caspase 3
Toxicity
Weight Loss
Assays
Cell Survival

Keywords

  • Cancer therapy
  • Gastric cancer
  • Hsp90
  • Hsp90 inhibitor
  • Molecular chaperone

ASJC Scopus subject areas

  • Biochemistry
  • Pharmacology

Cite this

Lu, C., Liu, D., Jin, J., Deokar, H., Zhang, Y., Buolamwini, J. K., ... Chen, X. (2013). Inhibition of gastric tumor growth by a novel Hsp90 inhibitor. Biochemical Pharmacology, 85(9), 1246-1256. https://doi.org/10.1016/j.bcp.2013.02.003

Inhibition of gastric tumor growth by a novel Hsp90 inhibitor. / Lu, Chunwan; Liu, Di; Jin, Jing; Deokar, Hemantkumar; Zhang, Yi; Buolamwini, John K.; Yu, Xiaoming; Yan, Chunhong; Chen, Xiaoguang.

In: Biochemical Pharmacology, Vol. 85, No. 9, 01.05.2013, p. 1246-1256.

Research output: Contribution to journalArticle

Lu, C, Liu, D, Jin, J, Deokar, H, Zhang, Y, Buolamwini, JK, Yu, X, Yan, C & Chen, X 2013, 'Inhibition of gastric tumor growth by a novel Hsp90 inhibitor', Biochemical Pharmacology, vol. 85, no. 9, pp. 1246-1256. https://doi.org/10.1016/j.bcp.2013.02.003
Lu C, Liu D, Jin J, Deokar H, Zhang Y, Buolamwini JK et al. Inhibition of gastric tumor growth by a novel Hsp90 inhibitor. Biochemical Pharmacology. 2013 May 1;85(9):1246-1256. https://doi.org/10.1016/j.bcp.2013.02.003
Lu, Chunwan ; Liu, Di ; Jin, Jing ; Deokar, Hemantkumar ; Zhang, Yi ; Buolamwini, John K. ; Yu, Xiaoming ; Yan, Chunhong ; Chen, Xiaoguang. / Inhibition of gastric tumor growth by a novel Hsp90 inhibitor. In: Biochemical Pharmacology. 2013 ; Vol. 85, No. 9. pp. 1246-1256.
@article{8af55a9f357e4468967591f4faacfd36,
title = "Inhibition of gastric tumor growth by a novel Hsp90 inhibitor",
abstract = "Heat shock protein 90 (Hsp90) is a molecular chaperone engaging in multiple cellular signaling by stabilizing oncoproteins (e.g. Akt and c-Raf) in tumor cells. Whereas Hsp90 inhibitors such as 17-AAG exert promising antitumor effects in clinical trials, current efforts focus on developing agents targeting Hsp90 with improved efficacy and lower toxicity. Using a fluorescence polarization assay, we screened over a hundred of synthetic small molecules and identified a resorcinol derivative LD053 that bound the Hsp90 ATP-binding pocket. The binding of LD053 to Hsp90 dissociated the co-chaperone protein cdc37 from Hsp90, resulting in destabilization of Akt and c-Raf and subsequent inhibition of PI3K/Akt and c-Raf/Mek/Erk signaling in BGC823 gastric cancer cells. As a consequence, LD053 decreased cancer cell viability and induced apoptosis evidenced by increased subG0/G1 cell population and increased cleavage of caspase 3 and PARP. Interestingly, normal human cells appeared insensitive to LD053 treatments. Consistent with its in vitro anticancer activities, LD053 significantly inhibited growth of BGC823 xenografts in nude mice without apparent body weight loss. These results thus demonstrate that LD053 is a novel Hsp90 inhibitor and has potential to be used to treat gastric cancer.",
keywords = "Cancer therapy, Gastric cancer, Hsp90, Hsp90 inhibitor, Molecular chaperone",
author = "Chunwan Lu and Di Liu and Jing Jin and Hemantkumar Deokar and Yi Zhang and Buolamwini, {John K.} and Xiaoming Yu and Chunhong Yan and Xiaoguang Chen",
year = "2013",
month = "5",
day = "1",
doi = "10.1016/j.bcp.2013.02.003",
language = "English (US)",
volume = "85",
pages = "1246--1256",
journal = "Biochemical Pharmacology",
issn = "0006-2952",
publisher = "Elsevier Inc.",
number = "9",

}

TY - JOUR

T1 - Inhibition of gastric tumor growth by a novel Hsp90 inhibitor

AU - Lu, Chunwan

AU - Liu, Di

AU - Jin, Jing

AU - Deokar, Hemantkumar

AU - Zhang, Yi

AU - Buolamwini, John K.

AU - Yu, Xiaoming

AU - Yan, Chunhong

AU - Chen, Xiaoguang

PY - 2013/5/1

Y1 - 2013/5/1

N2 - Heat shock protein 90 (Hsp90) is a molecular chaperone engaging in multiple cellular signaling by stabilizing oncoproteins (e.g. Akt and c-Raf) in tumor cells. Whereas Hsp90 inhibitors such as 17-AAG exert promising antitumor effects in clinical trials, current efforts focus on developing agents targeting Hsp90 with improved efficacy and lower toxicity. Using a fluorescence polarization assay, we screened over a hundred of synthetic small molecules and identified a resorcinol derivative LD053 that bound the Hsp90 ATP-binding pocket. The binding of LD053 to Hsp90 dissociated the co-chaperone protein cdc37 from Hsp90, resulting in destabilization of Akt and c-Raf and subsequent inhibition of PI3K/Akt and c-Raf/Mek/Erk signaling in BGC823 gastric cancer cells. As a consequence, LD053 decreased cancer cell viability and induced apoptosis evidenced by increased subG0/G1 cell population and increased cleavage of caspase 3 and PARP. Interestingly, normal human cells appeared insensitive to LD053 treatments. Consistent with its in vitro anticancer activities, LD053 significantly inhibited growth of BGC823 xenografts in nude mice without apparent body weight loss. These results thus demonstrate that LD053 is a novel Hsp90 inhibitor and has potential to be used to treat gastric cancer.

AB - Heat shock protein 90 (Hsp90) is a molecular chaperone engaging in multiple cellular signaling by stabilizing oncoproteins (e.g. Akt and c-Raf) in tumor cells. Whereas Hsp90 inhibitors such as 17-AAG exert promising antitumor effects in clinical trials, current efforts focus on developing agents targeting Hsp90 with improved efficacy and lower toxicity. Using a fluorescence polarization assay, we screened over a hundred of synthetic small molecules and identified a resorcinol derivative LD053 that bound the Hsp90 ATP-binding pocket. The binding of LD053 to Hsp90 dissociated the co-chaperone protein cdc37 from Hsp90, resulting in destabilization of Akt and c-Raf and subsequent inhibition of PI3K/Akt and c-Raf/Mek/Erk signaling in BGC823 gastric cancer cells. As a consequence, LD053 decreased cancer cell viability and induced apoptosis evidenced by increased subG0/G1 cell population and increased cleavage of caspase 3 and PARP. Interestingly, normal human cells appeared insensitive to LD053 treatments. Consistent with its in vitro anticancer activities, LD053 significantly inhibited growth of BGC823 xenografts in nude mice without apparent body weight loss. These results thus demonstrate that LD053 is a novel Hsp90 inhibitor and has potential to be used to treat gastric cancer.

KW - Cancer therapy

KW - Gastric cancer

KW - Hsp90

KW - Hsp90 inhibitor

KW - Molecular chaperone

UR - http://www.scopus.com/inward/record.url?scp=84875753717&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84875753717&partnerID=8YFLogxK

U2 - 10.1016/j.bcp.2013.02.003

DO - 10.1016/j.bcp.2013.02.003

M3 - Article

C2 - 23415900

AN - SCOPUS:84875753717

VL - 85

SP - 1246

EP - 1256

JO - Biochemical Pharmacology

JF - Biochemical Pharmacology

SN - 0006-2952

IS - 9

ER -